Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019
MD Spyridon G Deftereos, PhD Georgios Giannopoulos, MD, PhD Dimitrios A Vrachatis, PhD Gerasimos D Siasos, PhD Sotiria G Giotaki, MD Panagiotis Gargalianos, MD, PhD Simeon Metallidis, PhD George Sianos, PhD Stefanos Baltagiannis, MD, MSc Periklis Panagopoulos, PhD Konstantinos Dolianitis, MD, MSc Efthalia Randou, MD Konstantinos Syrigos, MD, PhD Anastasia Kotanidou, PhD Nikolaos G Koulouris, PhD Haralampos Milionis, PhD Nikolaos Sipsas, PhD Charalampos Gogos, PhD George Tsoukalas, PhD Christoforos D Olympios, PhD Eleftheria Tsagalou, MD, PhD; Ilias Ilias Migdalis, PhD Styliani Gerakari, MD Christos Angelidis, MD Dimitrios Alexopoulos, PhD Pericles Davlouros, PhD George Hahalis, MD, PhD; Ioannis Ioannis Kanonidis, PhD Demosthenes Katritsis, PhD Theofilos Kolettis, PhD Antonios S Manolis, PhD Lampros Michalis, MD, PhD Katerina K Naka, PhD Vlasios N Pyrgakis, Konstantinos P Toutouzas, PhD Filippos Triposkiadis, PhD Konstantinos Tsioufis, PhD Emmanouil Vavouranakis, Luis Martinèz-Dolz, MD, PhD Bernhard Reimers, MD Giulio G Stefanini, PhD; Michael Cleman, PhD; John Goudevenos, PhD Sotirios Tsiodras, MD, PhD Dimitrios Tousoulis, PhD Efstathios Iliodromitis, MD, PhD Roxana Mehran, PhD George Dangas, PhD Christodoulos Stefanadis
JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136
IMPORTANCE Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable safety profile. OBJECTIVE To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19). DESIGN, SETTING, AND PARTICIPANTS In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27, 2020, to either standard medical treatment or colchicine with standard medical treatment. The study took place in 16 tertiary hospitals in Greece. INTERVENTION Colchicine administration (1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) with standard medical treatment for as long as 3 weeks.
MAIN OUTCOMES AND MEASURES Primary end points were (1) maximum high-sensitivity cardiac troponin level; (2) time for C-reactive protein to reach more than 3 times the upper reference limit; and (3) time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death. Secondary end points were (1) the percentage of participants requiring mechanical ventilation, (2) all-cause mortality, and (3) number, type, severity, and seriousness of adverse events. The primary efficacy analysis was performed on an intentionto-treat basis. RESULTS A total of 105 patients were evaluated (61 [58.1%] men; median [interquartile range] age, 64 [54-76] years) with 50 (47.6%) randomized to the control group and 55 (52.4%) to the colchicine group. Median (interquartile range) peak high-sensitivity cardiac troponin values were 0.0112 (0.0043-0.0093) ng/mL in the control group and 0.008 (0.004-0.0135) ng/mL in the colchicine group (P = .34). Median (interquartile range) maximum C-reactive protein levels were 4.5 (1.4-8.9) mg/dL vs 3.1 (0.8-9.8) mg/dL (P = .73), respectively. The clinical primary end point rate was 14.0% in (continued) Key Points Question Is the receipt of colchicine among patients hospitalized with symptomatic coronavirus disease 2019 associated with clinical benefit? Findings In this randomized clinical trial of 105 patients, the rate of the primary clinical end point (clinical deterioration) was higher in the control group than in the colchicine group, and the time to clinical deterioration was shorter in the control group than in the colchicine arm. No difference was observed in the primary biochemical end point (highsensitivity troponin concentration), but patients in the colchicine group had a smaller increase in dimerized plasma fragment D compared with patients in the control group. Meaning The hypothesis-generating findings of this study suggest a role for colchicine in the treatment of patients with..
ARTICLE INFORMATION Accepted for Publication: May 29, 2020. Published: June 24, 2020. doi:10.1001/jamanetworkopen.2020.13136 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Deftereos SG et al. JAMA Network Open.
References
Acquisition, Giannopoulos, Vrachatis, Giotaki, Gargalianos et al., Critical revision of the manuscript for important intellectual content: Deftereos, Vrachatis
Administrative, Deftereos, Vrachatis, Gargalianos, Sianos et al., and Spectranetics/Philips/Volcano; receiving nonfinancial support from Idorsia Pharmaceuticals and Regeneron Pharmaceuticals; receiving
Agorogianni, Md, None
Balis, Md, First Intensive Care Unit, General Hospital Evangelismos
Baraboutis, Md, None
Barmparessou, Md, First
Bikdeli, Madhavan, Jimenez, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J Am Coll Cardiol. Published,
doi:10.1016/j.jacc.2020.04.031Bobotis, Md, None
Bouras, Md, None
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2001282Cardiology, General Hospital of Elefsina Thriasio
Castaño-Rodriguez, Honrubia, Gutiérrez-Álvarez, Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis, mBio,
doi:10.1128/mBio.02325-17Center, None
Chaidari, None
Chen, Li, Chen, Feng, Xiong, The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2, Cardiovasc Res,
doi:10.1093/cvr/cvaa078Chen, Moriyama, Chang, Ichinohe, Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 Inflammasome,
doi:10.3389/fmicb.2019.00050Chronaiou, Md, Fourth Department of Pneumonology
Chrysanthidis, Md, None
Deftereos, Giannopoulos, Vrachatis, Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?, Eur Hear J Cardiovasc Pharmacother,
doi:10.1093/ehjcvp/pvaa033Deftereos, None
Deftereos, Siasos, Giannopoulos, The Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19 study): rationale and study design, Hellenic J Cardiol,
doi:10.1016/j.hjc.2020.03.002Dolinay, Kim, Howrylak, Inflammasome-regulated cytokines are critical mediators of acute lung injury, Am J Respir Crit Care Med,
doi:10.1164/rccm.201201-0003OCFellah, Md, Department of Internal Medicine
Filippou, Md, None
Fountoulaki, Md, None
Garcia, Albaghdadi, Meraj, Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic, J Am Coll Cardiol,
doi:10.1016/j.jacc.2020.04.011Giaka, Md, None
Giotakis, Md, Second Department of Cardiology
Grigoropoulou, Md, None
Iliodromitis, Md, None
Jahaj, Md, First Intensive Care Unit
Jones, Crother, Gonzalez-Villalobos, The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury, Am J Respir Cell Mol Biol,
doi:10.1165/rcmb.2013-0087OCKalambokis, Md, None
Kaoukis, Md, None
Karageorgopoulos, Md, None
Karamvakalis, Md, None
Katsianos, Md, None
Kekeris, Md, None
Kochiadakis, Md, None
Kollias, Md, None
Kolokathis, Md, None
Komis, Md, Effect of Colchicine on Biomarkers and Clinical Outcomes in Patients Hospitalized With COVID-19, Department of JAMA Network Open | Infectious Diseases
Konstantinos, Kyriakoulis, Md, None
Koromilias, Md, First Department of Pneumonology
Kossyvakis, Md, None
Kotsamidi, Md, None
Kotsia, Md, None
Kyriakidou, Md, None
Laparidou, Md, None
Lezgidis, Md, Mpodosakio General Hospital of Ptolemaida
Li, Ren, Jiang, Zhu, Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury, Mol Med Rep,
doi:10.3892/mmr.2018.9427Loli, Md, None
Maniatopoulou, Md, None
Marques-Da-Silva, Chaves, Castro, Coutinho-Silva, Guimaraes et al., Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action,
doi:10.1038/ni.2550Mavrogiannaki, Md, None
Melidou, Md, None
Moussas, Md, None
Mparlampa, Md, None
Neroutsos, Md, None
Nikolaidou, Md, None
Ntekouan, Md, None
Ntemos, Md, None
Oikonomou, Md, None
Palaiologos, Md, None
Panteli, Md, None
Papathanasiou, Md, None
Paraskevi, Fragkou, Md, None
Parthenakis, Md, None
Pavlidou, Md, None
Petrakis, Md, Second Department of Internal Medicine
Poulakou, Md, None
Poulios, Md, None
Salvaras, Md, Department of Internal Medicine, Mpodosakio General Hospital of Ptolemaida
Sanz-Sánchez, Md, Cardio Center
Sarri, Md, None
Schulz, Altman, Moher, Group, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials, BMC Med,
doi:10.1186/1741-7015-8-18Semertzidis, Md, None
Shah, Pillinger, Zhong, Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial, Circ Cardiovasc Interv,
doi:10.1161/CIRCINTERVENTIONS.119.008717Shi, Nabar, Huang, Kehrl, SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes, Cell Death Discov,
doi:10.1038/s41420-019-0181-7Siu, Yuen, Castaño-Rodriguez, Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC, FASEB J,
doi:10.1096/fj.201802418RSpyridon, Louvros, Md, None
Stamatios, Tsouroulas, Md, None
Stanitsa, Md, None
Styliadis, Md, None
Tardif, Kouz, Waters, Efficacy and safety of low-dose colchicine after myocardial infarction, N Engl J Med,
doi:10.1056/NEJMoa1912388Temberikidis, Md, First Intensive Care Unit
Thanos, Md, None
Theodorakis, Md, Missolonghi General Hospital, Missolonghi, Greece
Touloumenidis, Md, None
Trikas, Md, None
Tsachouridou, Md, None
Tsiachris, Md, None
Tsiakas, Md, None
Tsioufis, Md, None
Tsitsinakis, Md, None
Tzouvelekis, Md, First Department of Pneumonology
Vagias, Md, None
Walls, Park, Tortorici, Wall, Mcguire et al., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell,
doi:10.1016/j.cell.2020.02.058Xarras, Md, None
Yannou, Md, None
Yiagoulis, Md, None
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3
